Roche Holding AG (OTCMKTS:RHHBY) Short Interest Down 18.2% in June

Roche Holding AG (OTCMKTS:RHHBY) was the recipient of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totalling 5,786,200 shares, a decrease of 18.2% from the May 31st total of 7,077,300 shares. Based on an average trading volume of 4,565,500 shares, the short-interest ratio is presently 1.3 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RHHBY. Wetzel Investment Advisors Inc. acquired a new stake in Roche during the fourth quarter worth about $53,000. Rhumbline Advisers raised its stake in shares of Roche by 11.2% during the 3rd quarter. Rhumbline Advisers now owns 96,751 shares of the company’s stock worth $3,283,000 after buying an additional 9,730 shares during the period. OLD National Bancorp IN grew its stake in Roche by 2.0% in the 3rd quarter. OLD National Bancorp IN now owns 251,843 shares of the company’s stock valued at $8,619,000 after acquiring an additional 4,956 shares during the period. Ramirez Asset Management Inc. purchased a new stake in Roche in the 3rd quarter worth $2,575,000. Finally, HighPoint Advisor Group LLC acquired a new stake in shares of Roche in the fourth quarter valued at about $373,000.

Roche Stock Down 0.7 %

OTCMKTS RHHBY opened at $34.67 on Friday. Roche has a 52-week low of $29.20 and a 52-week high of $39.92. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.75. The firm’s 50 day moving average price is $32.35 and its 200-day moving average price is $33.22.

Wall Street Analyst Weigh In

Several research firms recently weighed in on RHHBY. The Goldman Sachs Group started coverage on shares of Roche in a research note on Thursday, May 30th. They set a “sell” rating for the company. Argus restated a “hold” rating on shares of Roche in a report on Monday, March 4th. Finally, Deutsche Bank Aktiengesellschaft upgraded Roche from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $40.00.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.